In this manner, Johansson et al. analyzed the pharmacogenomic profile of patient-derived GBM cell cultures with 1544 drugs and stated that the response to proteasome inhibitors is correlated with TP53 and CDKN2A/B variations [88]. This evidence concerns the gene TP53 and glioblastoma.